Raymond James Financial Inc Black Diamond Therapeutics, Inc. Transaction History
Raymond James Financial Inc
- $299 Billion
- Q3 2025
A detailed history of Raymond James Financial Inc transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Raymond James Financial Inc holds 17,215 shares of BDTX stock, worth $72,475. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,215
Previous 36,888
53.33%
Holding current value
$72,475
Previous $91,000
30.77%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BDTX
# of Institutions
97Shares Held
41.5MCall Options Held
68.7KPut Options Held
0-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$45.2 Million0.02% of portfolio
-
Vestal Point Capital, LP New York, NY5.55MShares$23.4 Million0.95% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$18.7 Million1.03% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$13.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.19MShares$9.22 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $153M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...